Halozyme [HALO] vs Praxis Precision [PRAX] Detailed Stock Comparison

Halozyme Therapeutics Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Halozyme Therapeutics Inc. wins in 10 metrics, Praxis Precision Medicines Inc. wins in 4 metrics, with 0 ties. Halozyme Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Halozyme Therapeutics Inc. Praxis Precision Medicines Inc. Better
P/E Ratio (TTM) 26.72 N/A N/A
Price-to-Book Ratio 165.24 9.46 Praxis Precision Medicines Inc.
Debt-to-Equity Ratio 4,460.19 0.01 Praxis Precision Medicines Inc.
PEG Ratio -0.13 -38.31 Halozyme Therapeutics Inc.
EV/EBITDA 11.26 -26.32 Halozyme Therapeutics Inc.
Profit Margin (TTM) 22.69% 0.00% Halozyme Therapeutics Inc.
Operating Margin (TTM) 56.31% 0.00% Halozyme Therapeutics Inc.
EBITDA Margin (TTM) 56.31% N/A N/A
Return on Equity 153.59% -45.83% Halozyme Therapeutics Inc.
Return on Assets (TTM) 22.24% -28.69% Halozyme Therapeutics Inc.
Free Cash Flow (TTM) $356.82M $-249.12M Halozyme Therapeutics Inc.
1-Year Return 18.67% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 5.80 N/A N/A
Enterprise Value $10.11B $8.58B Halozyme Therapeutics Inc.
EV/Revenue Ratio 7.24 N/A N/A
Gross Profit Margin (TTM) 82.56% N/A N/A
Revenue per Share (TTM) $12 N/A N/A
Earnings per Share (Diluted) $2.56 $-13.48 Halozyme Therapeutics Inc.
Beta (Stock Volatility) 1.03 2.97 Halozyme Therapeutics Inc.
Short % of Float 15.34% 14.21% Praxis Precision Medicines Inc.

Halozyme Therapeutics Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

HALO
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Halozyme Therapeutics Inc.5.36%-3.55%2.65%-5.11%-0.39%-5.73%
Praxis Precision Medicines Inc.8.08%-26.51%-23.68%-22.06%43.85%-10.03%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Halozyme Therapeutics Inc.18.67%98.21%68.58%590.97%981.95%2,561.60%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Halozyme Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricHALOPRAX
Market Information
Market Cap i$7.89B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,358,440391,453
90 Day Avg. Volume i1,460,203416,321
Last Close$69.83$278.93
52 Week Range$51.06 - $82.22$37.19 - $366.52
% from 52W High-15.07%-23.90%
All-Time High$82.22 (Feb 09, 2026)$914.27 (Jan 04, 2021)
% from All-Time High-15.07%-69.49%
Growth Metrics
Quarterly Revenue Growth0.52%N/A
Quarterly Earnings Growth0.52%-1.00%
Financial Health
Profit Margin (TTM) i0.23%0.00%
Operating Margin (TTM) i0.56%0.00%
Return on Equity (TTM) i1.54%-0.46%
Debt to Equity (MRQ) i4,460.190.01
Cash & Liquidity
Book Value per Share (MRQ)$0.41$34.85
Cash per Share (MRQ)$1.21$21.52
Operating Cash Flow (TTM) i$651.56M$-249,068,000
Levered Free Cash Flow (TTM) i$184.83M$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Halozyme Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricHALO (Apr 24, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i26.72N/A
Forward P/E i6.94-38.31
PEG Ratio i-0.13-38.31
Price to Sales (TTM) i5.80N/A
Price to Book (MRQ) i165.249.46
Market Capitalization
Market Capitalization i$7.89B$9.60B
Enterprise Value i$10.11B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i7.24N/A
Enterprise to EBITDA i11.26-26.32
Risk & Other Metrics
Beta i1.032.97
Book Value per Share (MRQ) i$0.41$34.85

Financial Statements Comparison: Halozyme Therapeutics Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHALO (2025)PRAX (2025)
Revenue/Sales i1.40B0
Cost of Goods Sold i228.77MN/A
COGS % of Revenue i16.4%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i81.49M267.12M
Operating Income (EBIT) i802.59M-326.20M
Operating Margin i57.5%-
EBITDA i890.64M-326.06M
EBITDA Margin i63.8%-
Pre-Tax Income i466.88M-303.27M
Pre-Tax Income % of Revenue i33.4%-
Income Tax i149.99MN/A
Income Tax % of Revenue i10.7%-
Net Income (Profit) i316.89M-303.27M
Profit Margin i22.7%-

Balance Sheet & Liquidity Metrics

MetricHALO (2025)PRAX (2025)
Cash & Equivalents i133.82M357.33M
Total Current Assets i825.21M610.91M
Total Current Assets % of Revenue i59.1%-
Total Current Liabilities i177.09M59.77M
Total Current Liabilities % of Revenue i12.7%-
Long-Term Debt i2.14B0
Long-Term Debt % of Revenue i153.4%-
Total Shareholders Equity i48.81M878.14M
Retained Earnings i54.79M-1.14B
Retained Earnings % of Revenue i3.9%-
Property, Plant & Equipment i97.86M415,000

Cash Flow Statement Comparison

MetricHALO (2025)PRAX (2025)
Operating Cash Flow i630.45M-257.32M
Operating Cash Flow % of Revenue i45.1%-
Capital Expenditures i-6.97M-56,000
Free Cash Flow i356.82M-249.12M
FCF Margin i25.5%-
Debt Repayment i-1.02BN/A
Common Stock Repurchase i-342.37MN/A

Short Interest & Institutional Ownership Analysis

MetricHALOPRAX
Shares Short i14.05M3.95M
Short Ratio i9.459.07
Short % of Float i15.34%14.21%
Shares Outstanding i117.78M25.20M
Float Shares i116.71M25.78M
% Held by Insiders i1.09%0.40%
% Held by Institutions i107.46%106.12%
% Held by Public i-8.55%-6.52%

Dividend Analysis & Yield Comparison: Halozyme Therapeutics Inc. vs Praxis Precision Medicines Inc.

MetricHALOPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A